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Abstract
Changes in cerebral blood flow (CBF) can be assessed directly with xenon
clearance (XeC) or indirectly by measuring changes in middle cerebral artery
blood velocity (Vmca) with transcranial Doppler (TCD). The aim of this study
was to compare the changes in CBF and Vmca following caffeine ingestion.
Nineteen patients (age 48–86, recovering from an acute stroke) and ten
controls (age 52–85) were each studied twice. Bilateral measurements of
CBF and Vmca were made before and after ingestion of 250 mg caffeine or
matched placebo. The percentage change in CBF and Vmca after caffeine was
calculated. Full results (CBF and Vmca) were obtained from 14 patients and
9 controls. There was no significant difference between patients and controls,
so results were combined.
Caffeine reduced CBF by 22% (95% confidence interval (CI) = 17% to
28%) and reduced Vmca by 13% (95% CI = 10% to 17%). The fall in Vmca
was significantly less than that in CBF (p = 0.0016), showing that caffeine
reduces mca diameter. Analysis based on Poiseuille flow in the arterioles
suggests that caffeine reduced arteriole diameter by 5.9% (95% CI = 4.6% to
7.3%) and mca diameter by 4.3% (95% CI = 2.0% to 6.6%).
TCD is being used as an alternative to XeC for assessing the effect of
vasoconstrictors and vasodilators on CBF. This study has demonstrated that
mca diameter can be changed by the vasoactive agents, and that changes in
Vmca do not necessarily reflect changes in CBF.
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1. Introduction
Changes in cerebral blood flow (CBF) can be assessed either directly with xenon clearance
(XeC) or indirectly with transcranial Doppler (TCD) (Obrist and Wilkinson 1990, Newell and
Aaslid 1992). XeC uses an array of gamma-ray detectors around the head to measure the
rate of washout of radioactive xenon administered in the inhaled air. TCD uses an ultrasound
probe on the side of the head to measure the time average of the instantaneous maximum blood
velocity in the middle cerebral artery (Vmca). Fractional change in Vmca should be equal
to fractional change in CBF provided vessel diameter and velocity profile remain constant
(Kontos 1989).
It is well known that caffeine ingestion causes an acute reduction in CBF. Oral
administration of 250 mg caffeine to healthy young volunteers after at least 2 h abstinence
reduced CBF by 18% (Mathew and Wilson 1985) and intravenous infusion of 250 mg of
caffeine after 12 h abstinence reduced whole brain CBF by an average of 31% (Cameron et al
1990). There is no evidence that this reduction in CBF causes any problems in the normal
population in whom there is an adequate cerebral perfusion reserve, but there may be
implications in ischaemic stroke patients. An ischaemic stroke is caused by a reduction
in blood supply to an area of the brain leading to localized infarction, and there may be regions
of hypo-perfusion around the infarct which could be vulnerable to any further flow reduction
(Kaufmann et al 1999).
We have already used TCD to show that 250 mg caffeine reduces Vmca by 13% in patients
recovering from an ischaemic stroke in the middle cerebral artery (mca) territory (Lunt et al
2002). Caffeine of 250 mg is equivalent to two 150 ml cups of filter coffee or four cups of instant
coffee or five to nine cups of tea depending on the brewing time (Bunker and McWilliams
1979). The aim of this study was to compare the changes in Vmca and CBF in stroke patients
following caffeine ingestion to determine whether the change in Vmca does reflect a change
in CBF.
2. Materials and methods
Nineteen patients (age 48–86) and ten controls (age 52–85) were each studied twice
using a randomized double-blind cross-over design. Patients were selected from the
Stroke Rehabilitation Unit at Christchurch Hospital and from Acute Stroke Units at Royal
Bournemouth and Southampton General Hospitals. All were recovering from an ischaemic
stroke in the territory of a middle cerebral artery, diagnosis having been confirmed by clinical
findings and consistent computed tomography scan appearances. The studies were performed
at Southampton General Hospital. Ethical approval was obtained from the local Ethics
Committees.
Before each study, subjects abstained from caffeinated drinks for 48 h. Each study was
performed with the subject lying supine in a quiet room. Two baseline CBF measurements
and three baseline Vmca measurements were obtained bilaterally. Subjects were then given a
capsule containing either 250 mg of caffeine or placebo, and the CBF measurements repeated
40 and 60 min after administration. Four further Vmca measurements were obtained, two at
30 min and two at 90 min after administration.
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The CBF measurements were made using a Novo Cerebrograph 32c instrument,
(manufactured by Novo Diagnostic Systems, Denmark). The subject inhaled air containing
133Xe in a concentration of 110 MBq l−1 by means of a re-breathing administration system for
1 min and then continued to breathe normal air through the mask for the next 4 min to collect
exhaust xenon. The rate of removal of the isotope from the brain was monitored throughout
the 4 min and for a further 6 min by tracing the progressive change in radioactivity with a
system of 16 collimated scintillation detectors mounted on a helmet. The impulse response
function was determined by deconvolution with the curve of activity in the airway. CBF
was calculated from the rate of washout of the impulse response using the initial slope index
(Risberg and Prohovnik 1981).
The Vmca measurements were made using a transcranial Doppler unit (PCDop842,
Scimed Ltd, Bristol, UK). The unit displayed the Doppler spectrum continuously, identified
the maximum frequency envelope and converted frequency to velocity assuming blood flow
was directly towards the probe. Once an optimum signal had been obtained, an 8 s sample
was saved and the average of the maximum velocity envelope (Vmca) read from the TCD
display. For each reading the operator manipulated the probe to find the maximum velocity
signal through the temporal window. Each measurement consisted of three readings on each
side.
At the end of each study, the subject was allowed to take their normal beverages until 48 h
before any subsequent study. There was a gap of at least one week between studies to allow
washout of any administered caffeine.
For each subject the mean CBF on each side of the brain before and after medication
was calculated by averaging the results from the eight detectors on that side. The two
initial measurements were then averaged to obtain the baseline CBF and the subsequent two
measurements averaged to obtain the post-medication CBF. For the Vmca measurements, the
maximum of each set of three readings was used. Baseline Vmca on each side was obtained
by averaging the three measurements before medication, and post-medication Vmca obtained
by averaging the four post-medication measurements.
After the code was broken, the effect of caffeine was found for each hemisphere separately
by subtracting the change after placebo from the change after caffeine and these were averaged
over all subjects. Overall percentage changes were calculated using averages of the pre-
medication measurements as baselines. Statistical significance was assessed using Student’s
t-test with 5% significance level.
3. Results
Full CBF results (both sides and both visits) were available from 19 patients (mean age
71 years, range 48–86 years) and 10 control subjects (mean age 69 years, range 52–85 years).
In some of these patients, it was not possible to obtain good TCD signals from both sides. Full
Vmca results were available from only 14 patients (mean age 70, range 48–86) and 9 control
subjects (mean age 68, range 52–85) (table 1 and figures 1 and 2).
In the patients, there was no significant difference between the affected and unaffected
sides, so results from both were combined. Overall, the caffeine reduced CBF by 23.7%
(SD 13%, 95% confidence interval 18% to 30%) and Vmca by 15.5% (SD 9%, 95% CI 10%
to 20%). There was no significant correlation between the reduction in CBF and the age of
the patient (r = 0.23, p > 0.1).
In control subjects, there was no significant difference between the right and left sides
so results from both were combined. Overall, the caffeine reduced CBF by 18.9% (SD 10%,
95% CI = 12% to 26%) and Vmca by 11.2% (SD 11%, 95% CI = 3% to 19%). There
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Figure 1. Change in CBF after tablet—patients and controls (mean ±1 SEM).
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Figure 2. Change in Vmca after tablet—patients and controls (mean ±1 SEM).
Table 1. Summary of results.
CBF (ml/100 g min−1) Vmca (cm s−1)
Affected side Unaffected side Affected side Unaffected side
(a) Patients
Baseline 42.6 43.2 55.7 52.2
Fall after caffeine 9.0 9.2 8.6 8.0
Fall after placebo −1.0 −1.1 −0.4 0.3
Fall (caffeine–placebo) 10.0 10.3 9.0 7.7
95% confidence interval 7.2–12.9 7.9–12.8 5.3–12.7 5.4–9.9
(b) Controls Right side Left side Right side Left side
Baseline 49.3 48.5 52.6 54.2
Fall after caffeine 10.6 10.5 7.1 5.4
Fall after placebo 1.3 1.4 −1.6 2.1
Fall (caffeine–placebo) 9.4 9.1 8.7 3.3
95% confidence interval 5.7–13.0 5.4–12.9 4.7–12.6 2.7–9.2
was again no significant correlation between the reduction in CBF and the age of the subject
(r = 0.10, p > 0.5).
These results confirm that the reduction in Vmca does reflect a real reduction in CBF.
However, it appears that the fall in Vmca is less than that in CBF. This was investigated in
more detail by comparing the percentage reductions in Vmca and CBF in individual subjects.
Full results were available from 23 subjects, 14 patients and 9 controls.
There was no significant difference between patients and controls, and between the
affected and non-affected sides of the patients. Results were therefore combined. Caffeine
reduced CBF by 22% (95% confidence interval (CI) = 17% to 28%) and reduced Vmca by
13% (95% CI = 10% to 17%). Comparison of the changes in individual subjects (figure 3)
showed that the fall in Vmca was significantly less than that in CBF (p = 0.0016).
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Figure 3. Comparison of fractional changes in Vmca and CBF in the individual subjects. The
points do not lie on the line of identity (dotted line) and the fall in Vmca was significantly less than
that in CBF ( p = 0.0016).
The consistency of the CBF and Vmca measurements was assessed by comparing
measurements made on the same subject on the same occasion. The standard deviation
of the difference between CBF measurements was 4.1 ml/100 gm min−1, and between Vmca
measurements was 4.1 cm s−1. Baseline CBF and Vmca and their inter-subject standard
deviations were estimated by comparing the pre-medication values in the different subjects.
For CBF, baseline and standard deviation were 45 and 7.3 ml/100 gm min−1, and for Vmca
they were 52 and 17.0 cm s−1.
4. Discussion
The different percentage changes in CBF and Vmca may arise because the two techniques
assess different parts of the brain, which respond differently to caffeine. The middle cerebral
artery supplies the parieto-temporal region of the brain, while the scintillation detectors were
also positioned over the occipital region. CBF results from the 19 patients and 10 controls
were therefore re-analysed using only the six parieto-temporal detectors on each side, but this
made no significant change in the results. There was a 23% reduction in CBF compared to
22% when all detectors were used.
The CBF measurements will include more of the flow in the superficial cortex, while the
middle cerebral artery supplies some deeper structures. Differences may occur if caffeine has
a different effect on the grey and white matter and if there are different proportions of grey
and white matter in these regions. The CBF measurements were re-analysed using a dual
slope model (Obrist and Wilkinson 1990) to determine the effect on grey matter alone, but
this made no significant change in the results. There was a 24% reduction in CBF to grey
matter compared to 22% to grey and white combined. This is consistent with the findings of
Field et al (2003) who used magnetic resonance imaging to study the effect of caffeine on
CBF to grey and white matter, and found that 250 mg caffeine reduced flow to grey matter by
23% and flow to white matter by 18%.
Differences between changes in CBF and Vmca can also be caused by changes in velocity
profile (Lunt et al 2000). However, profile changes will cause a larger change in Vmca than in
CBF (Lunt et al 2000), so cannot account for the lower change in Vmca found in the present
study.
Blood flow depends on the ratio of blood pressure and peripheral resistance. The reduction
in CBF after caffeine must therefore be caused by a reduction in blood pressure, an increase
in peripheral resistance, or a combination of the two. After caffeine, systolic blood pressure
fell by 1.4% (2.0 mmHg from a mean of 139 mmHg) and diastolic pressure fell by 0.7%
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(0.5 mmHg from a mean of 78 mmHg). These changes are far too small to account for the
22% fall in blood flow, so there must have been an increase in peripheral resistance.
The flow of an ideal fluid through a rigid tube is described by Poiseuille’s law. Under
the ideal conditions of steady established laminar flow, the resistance is proportional to the
fourth power of the tube radius. Under these conditions, a 22% fall in flow would be caused
by a 6% change in radius. Cerebral blood flow is controlled by arterioles, and many of the
assumptions of the theoretical analysis will not strictly apply. In particular, the arterioles are
elastic and the flow is pulsatile. In spite of these differences, our results (22% change in CBF
and 13% change in Vmca) are similar to those predicted by a steady-state model in which
arteriolar and mca radii change by the same proportion. If arteriolar radius reduces by 6%,
the flow through the arterioles would fall by 22% and the flow through the mca would also
fall by 22%. But, if the mca radius also reduces by 6%, the Vmca would only fall by 12%,
since the relation between velocity and flow would have changed. The validity of this model
is discussed further in section 5.
Even though the quantitative analysis may not be applicable, the difference between the
reduction in flow and the reduction in velocity indicates that caffeine reduces middle cerebral
artery diameter. This is an important result, since the use of transcranial Doppler as an
alternative to xenon clearance is often justified by the assumption that there is no change in
mca diameter.
There have been other studies examining whether vasoconstrictors or dilators change mca
diameter. Huber and Handa (1967) used angiography to show that the diameters of cerebral
arteries between 0.5 and 1.0 mm diameter were increased about 25% by the contrast agent
(Urografin 60%). Increasing PaCO2 from 40 to 57 mmHg through CO2 inhalation or injecting
30 mg papavarine also caused a 25% increase. However, the mca and vessels of similar calibre
(2.0 to 2.5 mm diameter) were increased by a much smaller amount (4% with CO2 inhalation).
Giller et al (1993) obtained similar results by measuring vessel diameters directly using
an operating microscope during craniotomy. End tidal CO2 was increased by an average of
14 mmHg, and this caused 18% diameter increase in mca branches but only 2% in the mca itself.
There have also been other studies examining the relationship between changes in blood
velocity and changes in flow. Dahl et al (1992) performed simultaneous TCD and XeC
measurements to validate the use of TCD for cerebral vasoreactivity studies with acetazolamide
as the stimulus. Intravenous administration of 1 g acetazolamide to 20 control subjects
increased average CBF and Vmca by 30% and 34%, respectively. Demolis et al (1996)
performed a similar study on 52 patients referred for cerebral vasoreactivity studies and found
a 39% increase in CBF and a 41% increase in Vmca. These results suggest that acetazolamide
causes similar changes in CBF and Vmca. However, Brauer et al (1998) also used 1 g
acetazolamide and found a 25% increase in CBF and a 41% increase in Vmca. Although
these results are somewhat inconsistent, there is no evidence that acetazolamide dilates both
the arterioles and the mca, since this would cause a lower increase in Vmca than in CBF.
This is important clinically, since acetazolamide is administered to stroke patients to assess
cerebral vasoreactivity. The effect of the acetazolamide is assessed by measuring changes in
CBF using XeC or changes in Vmca using TCD and the two have been shown to be equivalent
(Dahl et al 1992).
In summary, different vasodilators and vasoconstrictors have different effects on the mca
diameter. Acetazolamide appears to have little effect, carbon dioxide has some effect and
caffeine may have a greater effect, with the percentage change in mca radius comparable to
that in the flow-regulating vessels. However, if caffeine does have a consistent effect on all
vessels, there should be a consistent relationship between the changes in flow and velocity in
individual subjects. This is investigated below.
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5. Comparison of changes in velocity, flow and pressure in individual subjects
We have suggested above that caffeine may be causing the same percentage reduction in the
radius of mca and arterioles. This was based on the application of Poiseuille’s formula,
Q = π
8η
∂P
∂L
r4
where Q is the flow through a straight, rigid capillary tube; η the viscosity of the fluid, ∂P/∂L
the pressure gradient and r is the radius of the tube.
This formula will not strictly apply to arterioles because they are branched, curved,
elastic and carry pulsatile flow, but it suggests that mean flow in arterioles may be proportional
to (pressure gradient) × r4. There is only a small pressure drop in vessels proximal to the
arterioles, so the pressure gradient can be assumed to be proportional to the difference between
arterial blood pressure (ABP) and venous pressure. If cerebral venous pressure is assumed to
be zero, pressure gradient will be proportional to ABP and mean flow in the arterioles will be
proportional to ABP × r4. Hence, if q, P and r are the CBF, ABP and arteriole radius in a
subject and suffices 1 and 2 are before and after medication (caffeine or placebo),(
r2
r1
)4
= q2
q1
P1
P2
. (1)
This can be used to find the medication-related change in arteriole radius r in a given subject.
It is important to include the blood pressure, since changes in individual subjects were as high
as 15 mmHg between the pre-caffeine and post-caffeine measurements, although the average
change across all subjects was less than 1.5 mmHg.
Mca blood flow Q, radius R and mean blood velocity Vmean are related by
Q = πR2Vmean.
Transcranial Doppler measures the time-averaged maximum velocity (V ) instead of the mean.
The exact relationship between these depends on the velocity profile (Lunt et al 2000) but they
will be proportional if the profile remains constant. In this case,(
R2
R1
)2
= Q2
Q1
V1
V2
(2)
where subscripts 1 and 2 denote before and after medication.
Assuming that the percentage changes in flow in the arterioles and mca are equal to
the percentage change in CBF, equations (1) and (2) can be used to examine the changes
in arteriole and mca radii (r2/r1 and R2/R1 respectively) after caffeine and placebo. Results
are given in table 2. Caffeine causes significant changes in arteriole radius (r2/r1 = 0.941,
p < 0.001) and in mca radius (R2/R1 = 0.957, p < 0.001). Changes after placebo are not
statistically significant.
Comparison of r2/r1 and R2/R1 in individual subjects does not provide hard evidence that
these ratios are the same. In fact, the hypothesis that they are the same can be rejected at the
10% significance level ( p = 0.08).
Table 2. Mean fractional change in vessel radius assuming Poiseuille flow in the arterioles. Both
caffeine-induced changes are statistically significant.
Mca Mca Arteriole Arteriole
(mean change) (95% CI) (mean change) (95% CI)
After caffeine 0.957 0.934–0.980 0.941 0.927–0.954
After placebo 1.004 0.982–1.026 0.996 0.979–1.013
474 M J Lunt et al
The above analysis, based on Poiseuille flow in the arterioles, therefore suggests the
250 mg caffeine reduces arteriole diameter by 5.9%, and mca diameter by 4.3%. Both
changes are statistically significant.
6. Conclusions
This study has demonstrated that 250 mg caffeine reduces CBF by an average of 22% in
healthy volunteers and in patients recovering from an acute ischaemic stroke, and that both
cerebral hemispheres are affected equally. The caffeine causes a significantly smaller change
of 13% in Vmca, and this shows that caffeine reduces the mca diameter. Analysis based on
Poiseuille flow in the arterioles suggests that the 250 mg caffeine reduced arteriole diameter
by 5.9%, and mca diameter by 4.3%.
Transcranial Doppler is being used as an alternative to xenon clearance for assessing the
effect of vasoconstrictors and vasodilators on cerebral blood flow. This study has demonstrated
that mca diameter can be changed by the vasoactive agents, and that changes in Vmca do not
necessarily reflect changes in CBF.
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